BSX Stock Analysis: Buy, Sell, or Hold?
BSX - Boston Scientific Corp.
$43.06
0.38 (0.89%)
▲
5d:
-3.15%
30d:
-10.25%
90d:
-31.38%
BUY
HIGH Confidence
Analysis Updated: Jul 1, 2026 12:00 AM ET
Earnings: Jul 22, 2026
19d
Smart Money Accumulation
None View Scanner →
Strength: 10.0/10
Get Alerted When BSX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: BSX appears deeply undervalued. Market expects -15.8% annual earnings decline despite 100% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: BSX appears deeply undervalued. Market expects -15.8% annual earnings decline despite 100% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$102.53
Based on 7.3% avg growth
INTRINSIC VALUE TODAY
$63.66
32.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BSX is currently trading at $43.06, which is considered oversold relative to its 30-day fair value range of $44.02 to $50.00. From a valuation perspective, the stock is trading at a discount (Forward PE: 11.6) compared to its historical average (19.4). Remarkably, the market is currently pricing in an annual earnings decline of 15.8% over the next few years. This pessimistic expectation contrasts with the company's recent 100% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, BSX is in a strong downtrend. The price is currently testing key support at $42.25. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BSX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $75.00 (+74.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BSX is in a strong downtrend. The price is currently testing key support at $42.25. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BSX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $75.00 (+74.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$44.02 -
$50.00
Company Quality Score
67/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 74.2% below Wall St target ($75.00)
Trading Range Analysis
30-Day Trading Range
$44.02 -
$50.00
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$42.25
Resistance Level
$46.70
Current Trend
Strong Downtrend
Technical data as of
Jul 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.57
Wall Street Target
$75.00
(+74.2%)
Revenue Growth (YoY)
11.6%
Earnings Growth (YoY)
100.0%
Profit Margin
17.3%
Valuation Discount vs History
-15.8% cheaper
PE vs Historical
11.6 vs 19.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-15.8%
(market-implied from PE analysis)
1-Year Target
$38.75
(-10%)
2-Year Target
$34.88
(-19%)
3-Year Target
$31.39
(-27%)
3-Yr Target (if PE normalizes)
(PE: 12→19)
$52.61
(+22%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 10.6%)
$109.69
(+155%)
Base:
(SPY PE: 11.6, Growth: 10.6%)
$58.29
(+35%)
Bear:
(PE: 9.8, Growth: 10.6%)
$49.55
(+15%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 17.86 | Current EPS (TTM): $2.39
Bull Case
$73.08
(+70%)
Analyst growth 55.7%, PE expands to 19.6
Base Case
$66.43
(+54%)
Market implied 55.7%, PE stable at 17.9
Bear Case
$29.02
(-33%)
Severe decline -20.0%, PE contracts to 15.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 11.6 to 19.4
Stabilization Target:
$72.17
(+67.6%)
PE Expansion Potential:
+67.6%
Share & Embed Analysis
Last updated: July 01, 2026 10:43 PM ET
Data refreshes hourly during market hours. Next update: 11:43 PM
Data refreshes hourly during market hours. Next update: 11:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BSX showing a specific setup today?
Insider Activity (6 Months)
5
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
BUY
2026-03-30
Ro Khanna
SELL
2026-03-23
Ro Khanna
SELL
2026-02-24
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 65 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 56 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 63 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$240 | 61 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 59 HOLD |
Advanced BSX Option Strategies
Professional options setups generated by AI based on today's BSX price and gamma walls.
